OneMedNet Corp. (ONMD) regained compliance with Nasdaq’s $1.00 minimum bid price requirement after Nasdaq staff confirmed the common stock’s closing bid price was at least $1.00 per share for 10 consecutive business days, from September 29, 2026 through October 12, 2026. Nasdaq’s notice, received October 13, 2026, states that the matter is closed.
The company had received a notice of noncompliance on April 14, 2026, with a grace period until October 12, 2026 to regain compliance.
OneMedNet Corp (ONMD) director and 10% owner Thomas Kosasa purchased 129,758 common shares directly on October 7, 2026, at $5.78 per share. OneMedNet entered into a subscription agreement with Kosasa for a $750,000 investment. His reported direct holdings after the purchase were 1,983,573 shares; no Rule 10b5-1 plan is reported.
OneMedNet Corp’s Chief Medical Officer, director and 10% owner Jeffrey Yu purchased 45,126 common shares on October 9, 2026, through a subscription agreement for a $250,000 investment. The shares were valued at $5.54 per share, based on the issuer’s volume-weighted average price for the 10 trading days immediately before the purchase. Yu directly held 896,840 shares after the purchase. Separately, a trust for his children held 131,197 shares with an independent trustee; Yu said he had no investment control and disclaimed beneficial ownership. No Rule 10b5-1 plan is reported.
OneMedNet Corp (ONMD) Chief Financial Officer and director Robert Lawrence Golden reported direct grants of 35,000 restricted stock units on July 6, 2026, and 10,000 restricted stock units on January 1, 2026. The January award amount reflects the 1-for-10 reverse stock split on September 29, 2026. The July grant vests in installments subject to continued service; the January grant vests in full on December 31, 2026, subject to the Consulting Agreement terms.
Golden also reported direct sales of 8,500 common shares to cover tax obligations upon RSU vesting and settlement: 2,500 shares at $6.6000 per share on September 14, 3,000 at $6.3000 on September 15, and 3,000 at $6.6300 on September 21, 2026. No Rule 10b5-1 plan is reported.
OneMedNet Corp reported that its Chief Executive Officer and director, Aaron Green, was granted 65,000 restricted stock units on July 6, 2026, under its 2022 Equity Incentive Plan. Green sold 5,000 common shares at $7.3920 per share on September 22 and 1,667 at $6.4800 per share on September 24, 2026, to cover tax obligations upon RSU vesting and settlement; no Rule 10b5-1 plan is reported. The share amounts and prices reflect the issuer's 1-for-10 reverse stock split on September 29, 2026.
OneMedNet Corp. (ONMD) will implement a 1-for-10 reverse stock split effective at 12:01 a.m. Eastern Time on September 29, 2026; each 10 issued and outstanding common shares will become one share. The company says the split is intended to bring it into compliance with the Nasdaq Capital Market’s minimum bid price requirement.
The corporate-action description estimates outstanding shares will change from approximately 60,125,902 as of September 27, 2026, to approximately 6,012,591 after the split. The accompanying announcement separately gives approximately 59,286,450 shares as of September 24, 2026, and approximately 5,928,645 after the split. Fractional shares will be rounded up; authorized shares, par value and voting rights will not change.
OneMedNet Corporation (ONMD) stockholders approved an amendment to the Amended and Restated 2022 Equity Incentive Plan, increasing its authorized share count by 1,000,000 shares; the amendment became effective immediately upon approval. Stockholders also approved a charter amendment to effect a reverse stock split at a whole-number ratio from 1-for-5 to 1-for-20, with the ratio determined by the Board of Directors in its discretion.
At the September 18, 2026 annual meeting, stockholders elected Dr. Kenneth Alleyne, Sherry Coonse McCraw, and Dr. Jeffrey Yu as Class III directors for terms ending at the 2029 annual meeting, and ratified WithumSmith+Brown, PC as the independent registered public accounting firm for the year ending December 31, 2026. A total of 41,841,452 votes were represented in person or by proxy, equal to 70.57% of votes entitled to be cast and constituting a quorum.
OneMedNet Corp (ONMD) reported that Jeffrey Yu, a director, Chief Medical Officer and more-than-10% owner, entered into a subscription agreement to purchase 142,857 shares of common stock on September 10, 2026 for a $90,000 investment, valued at a $0.63 volume-weighted average price over the prior 10 trading days. Following this transaction, he holds 8,923,267 shares directly and an additional 1,311,970 shares are held indirectly in a trust for his children with an independent trustee; he disclaims beneficial ownership of the trust shares. No Rule 10b5-1 trading plan is reported.
OneMedNet Corporation (ONMD) is asking stockholders at its fully virtual 2026 annual meeting on September 18, 2026 to approve several key items. Stockholders will vote to elect three Class III directors (Kenneth Alleyne, Sherry Coonse McCraw, and Jeffrey Yu) to three-year terms, ratify WithumSmith+Brown, PC as independent auditor for 2026, approve an amendment and restatement of the 2022 Equity Incentive Plan adding 1,000,000 shares to the share reserve, and authorize the Board to implement a reverse stock split at a ratio between 1-for-5 and 1-for-20.
As of August 11, 2026, OneMedNet had 59,286,450 shares of common stock outstanding and was out of compliance with Nasdaq’s $1.00 minimum bid price requirement, with a cure period running until October 12, 2026. The Board states that a reverse split may be used to help regain compliance and maintain the Nasdaq Capital Market listing. The equity plan currently has 826,417 shares available and 4,217,303 shares subject to outstanding RSUs, and the company estimates the newly requested plan shares equal about 1.7% of outstanding stock.
OneMedNet Corporation, a healthcare software company focused on real-world data from medical imaging, reported continued operating losses and liquidity pressure for the quarter and six months ended June 30, 2026. Revenue was modest but growing, with quarterly revenue of $0.3 million, up from $0.2 million a year earlier, driven by higher data delivery volumes on its iRWD platform after decommissioning its legacy BEAM subscription product.
Despite this growth, the company posted a quarterly gross loss of $0.6 million, an operating loss of $2.3 million, and a six‑month net loss of $4.6 million. Cash and cash equivalents were only $0.4 million against total liabilities of $4.9 million and a stockholders’ deficit of $3.5 million, and management states that these conditions raise substantial doubt about its ability to continue as a going concern.
The company funded operations through related‑party equity subscriptions and a 2024 Standby Equity Purchase Agreement, issuing additional shares and expanding its share count to 59.3 million common shares outstanding as of August 11, 2026. It exited all Bitcoin holdings, recorded gains from warrant and SEPA derivative remeasurements, and in July 2026 entered a new $25.0 million SEPA with Yorkville. OneMedNet also discloses noncompliance with Nasdaq’s $1.00 minimum bid price requirement and ongoing material weaknesses in internal controls over financial reporting.